World Library  
Flag as Inappropriate
Email this Article

Martin Shkreli

Article Id: WHEBN0033759585
Reproduction Date:

Title: Martin Shkreli  
Author: World Heritage Encyclopedia
Language: English
Subject: Shkreli, Baruch College
Publisher: World Heritage Encyclopedia

Martin Shkreli

Martin Shkreli (born 1983) is an American-Albanian[1] hedge fund manager, specializing in healthcare, and is the founder of MSMB Capital Management, a multi-strategy hedge fund.[1]

He was the Chief Executive Officer of Retrophin LLC, a biotechnology firm founded in 2011.[2][3]

Early career

In 2000, Shkreli began working for Jim Cramer at Cramer, Berkowitz, & Co. He then spent three years at Intrepid Capital Management working in healthcare stock-picking under Steve Shapiro, a 'Tiger Cub' and protégé of Julian Robertson of Tiger Management.

Healthcare investing

Shkreli founded MSMB Capital Management (named after the two founding Portfolio Managers, Martin Shkreli and Marek Biestek) in 2009.[4]


Retrophin was created in February 2011 as a potential solution to Muscular Dystrophy.[5] It was created and run from the offices of MSMB Capital as a portfolio company. Retrophin is a biotechnology company dedicated to creating treatments for orphan diseases.[3] He was fired by the Board of Retrophin and replaced as CEO by Stephen Aselage in September 2014.


In August 2014, members of Shkreli's company were caught using Twitter accounts to impersonate gangster rappers to help promote Retrophin.[6] Shkreli has also been known to make controversial statements on Twitter about others.[7]

In September 2014 Retrophin acquired the rights to thiola, a drug used to treat the rare disease cystinuria. It was with Shkreli's as CEO that Retrophin introduced a 20-fold price increase for Thiola, despite no additional research and development costs incurred by obtaining these rights. [8] [9]

Shkreli has also came under fire from CREW (Citizens for Responsibility and Ethics in Washington) for the alleged manipulation of the FDA regulatory process in order to move stock prices for his own financial gain,[10] though these allegations did not result in any charges.


  1. ^ a b """Shqiptaro amerikani anëtar i revistës Forbes - financë "30 under 30. BotaSot. Dec 29, 2012. 
  2. ^ Nussbaum, Alex (Aug 3, 2011). "MSMB Capital Makes Unsolicited $378M Bid For AMAG Pharmaceuticals". Bloomberg. 
  3. ^ a b "Retrophin: About Us". 
  4. ^ "Pfizer Board comes under fire". Financial Times. Dec 8, 2010. 
  5. ^ "Retrophin Private Company Information". Business Week. Oct 26, 2011. 
  6. ^
  7. ^
  8. ^
  9. ^
  10. ^
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.